ANAVEX. NY TRÅD ÅRSRAPPORT 2021!!!!
-
Anavex ... Ikke mindre en to partnership nyt i dag af interesse.
Novartis og GSK:
GSKs partner Alector har nogle meget interessante tidlige data i frontotemporal dementia. En direkte konkurrent tl 3-71 vi afventer data fra.
Håbede lidt på Novartis som partner til Anavex....
Så gerne lidt fart på Anavex
-
Anavex ... Dagens webcast/fireside chat fra Evercore var igen en opmuntrene oplevelse. Helt forskellig fra kursudviklingen
Missling er inde i sagerne og udspørgeren var ligeså. Evercores mand var synligt imponeret over de historiske data og spurgte ind til hvordan de enkelte igangværende forsøg var powered - for at forsikre sig, at der er nok pts til at sikre signifikante resultater. Missling kunne redegøre tilfredstillende for de enkelte forsøg, hvor historiske data udgjorde beslutningsgrundlaget herfor.
Doseringsstørrelsen blev der spurgt til. Missling redegjorde for, at der næppe er problemer med overdosering og at der er tolerence for stoffet pænt over den dosering der er anvendt. For høj dosering ses kun at hæmme virkningen en anelse.
Følgende blev endnu engang bekræftet:
- Pivotale PD og PDD forsøg er ved at blive planlagt
- Readout for Avatar og 3-71 bekræftet igen til omkring nytårsskiftet
- Readout Excellence H122 og AD ph2/3 H222
- AD ph2/3 er et registreringsforsøg/pivotal, hvis data er stærke - her nævnte Missling Aduhelm som "bencmark" (mon det kan kaldes benchmark)
Nogle spændende uger forude selvom kursen kører sit eget løb indtil data kommer.
Bemærk at der i ovennævnte tråd er lidt benchmark til 3-71 forsøget i frontotemporal dementia, hvis effekt måles.
-
Anavex Solsen - fint resume!
Det var i hovedtræk en bekræftelse af, hvad Missling tidligere har meldt ud.
Ser ud til de har helt styr på den aktiv mængde 2-73 og samtidig har et pænt vindue op til en unødvendig overdossering i alle indikationer.FDA synes iflg. Missling begejstret for især RETT - og understregede, at hvis Avatar var overbevisende, så havde man meget sandsynligt nok til en godkendelse her, fordi det er en sjælden og alvorlig indikation.
Missling bekræftede også, at de med den 152 mill. $ på bogen kan financierer alt det de har og agter at sætte i gang de næste 3-5 år - UDEN at skulle hente nye penge.
(Tror dog, at Anavex som hidtil løbende sælger et mindre antal aktier, for at bevare vinduet på de ca. 4 år)For os der kender casen, var der som sagt ikke meget nyt - men for nye potentielle investorer må de beskrevne resultater og fremtidsudsigterne da virke ret tiltalende.
Tror også at flere nu har en anledning til at sætte sig lidt ind i, hvad Anavex egentlig har gang i.Husk Missling er på en RETT konference den 14. december!
-
Anavex. December præsentation.
Top-line data AVATAR: Potentially pivotal Phase 2/3 adult RTT clinical trial - expected YE 2021
Top-line data Phase 1 ANAVEX
3-71 clinical trial - expected YE 2021Ikke meget nyt ,men en bekræftelse af, at vi kan forvente data i december - spørgsmålet er så, hvor længe før en offentliggørelse/præsentation har Anavex kendskab til resultaterne?
Anavex udgør 0,92 % af XBI indekset, hvilket samlet faldt 4,4 % i dag - Anavex - 5,6 %.
Positive Avatar resultaterne vil forhåbentlig adskille os fra resten af div. indekser.State Street SPDR S&P Biotech ETF (XBI) Stock Price, News, Quote & History - Yahoo Finance
Find the latest State Street SPDR S&P Biotech ETF (XBI) stock quote, history, news and other vital information to help you with your stock trading and investing.
Yahoo Finance (finance.yahoo.com)
-
Anavex ... En givende debat over weekenden på Ihub og med et indlæg fra bl.a. MayoMobile med en opsummering/analyse af Anavex:
Anavex Life Sciences Corp (AVXL): Anavex Company Overview (Current as of 5...
MayoMobile: Anavex Company Overview (Current as of 5 Dec 2021)
InvestorsHub (investorshub.advfn.com)
Grønne bjælker i hver slide med interessante kommentarer fra forfatteren.
Lidt surrealistisk at læse om kurs 6.000
Ikke jeg tror på de 6.000. Men mindre kan jo også gøre det.
Første alvorlige test nærmer sig med Avatar data !
NB Stadig GAP ned til 15,5
-
Jo så godt the flotte opsummering fra super dygtige MayoMobile og er enig i at kurs 6000 er nok i overkanten. Hvis den når derop vil mange mennesker blive helt vildt rige: 167 aktier = 1mill$.
Jeg vil værre ovenud lykkelig hvis vi passer kurs 100 en dag som er mugligt hvis RETT data er gode og medfører godkendelse da flere indikatorer vil følge efter.
Ser ud til at vi åbner i minus i dag, håber på nyheder i morgen men jeg giver det 30-40% chance, nok større næste uge før RETT konference den 14.
-
øh hvorfor ikke kurs 6000, når Tesla er 10 gange mere vær end Toyota og Toyota laver 10-20 gange flere biler, så kan alt lade sig gøre, men jeg vil være glad for kurs 250 på et tidpunkt
-
Anavex Ja ham Mayo er super dygtig, mener han arbejder inden for analytiker eller bioteksektoren - han plejer også at være mere konservativ, så kurs 6000 er højt sat - mindre kan også gøre det. Tror desværre også, at Anavex er blevet opkøbt inden, hvilket jeg ikke håber sker - partneraftaler på enkelte indikationer ville dog på den korte bane give et større gennemslagskraft og større omsætning og nå ud til flere trængende patienter tidligere.
Avartar er nøglen - får vi den prop slået ud af bunden på whisky tønden, så er der ikke meget der kan stoppe casen - for ikke kun får vi sandsynligvis 2-73 på markedet i 2022, men lige så vigtig er, får vi bevist virkemåden MOA af 2-73 og derved sandsynliggøre at 2-73 også virker i de øvrige indikationer.
-
Anavex ... Helt korrekt Tasso1.
Det bliver derfor også med høj puls, at vi skal læse meddelelsen omkring Avatar
Hvis det mindre sandsynlige skulle ske, at det skuffer så har vi Excellence at falde tilbage på. Men aktien vil falde med mere end 50%
Mit klare indtryk er, at der er styr på det faglige og i Rett har der tidligere i patientgruppen været overbevisende data. Stadig lidt af en gåde for mig, at man ikke har taget dobbelt så mange pts ind i forsøget for en ekstra sikkerheds skyld. Men de har sikkert styr på det !
Bedste værn imod overtagelse er, at indgå flere partnerskaber kort efter evt gode Avatar data. Pt har de poison pill til at holde købere væk. Og den kan de vel opretholde længe....
Med muligheden for helt at ændre behandlingen indenfor CNS - i det mindste i større grupper indenfor de enkelte indikationer er potentialet til et meget høj Mcap til stede.
Tror de kan ramme 30% i royalty i de store indikationer, der udliciteres, samt pæne milestones (salg og regulatoriske).
Men ikke mindst så kan Anavex give håb i håbløse indikationer !!!
Time will show.
-
Anavex ... Acandia med gode resultater i Rett:
https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-positive-top-210500024.htmlMen med over 80% diarre i pts i rullestol ....
Effect size under 0,5 på målepunkter (Blarcamesine har rundt regnet 1)
Jeg tror godt, at Anavex kan slå det resultat.
Bemærk patientgruppen med hovedsaglig unge piger. Så passer bedre til sammenligning med Excellence.
-
Anavex ... MayoMobiles syn på Acandias forsøg (som kopi fra Ihub):
From MayoMobile on stocktwits---Brief Acadia Rett Result Summary:
Statistically significant findings in primary endpoints. Relatively low effect sizes.
Anavex's RS-001 low dose RSBQ scores were over 4x better than Acadia
17% of doses cohort dis-enrolled due to adverse effects.
- 80% of dosed patients had diarrhea
-26% of dosed patients experienced vomiting
Altså både sideeffekt og effekt forventes altså bedre for Blarcamesine. Bl.a. diarre er ikke set med Blarcamesine.
De gode P-værdier i Acandias forsøg er opnået i et forsøg med 187 pts.
Anavex har forsøg i størrelsesordene 30-90. Men bedre effekt med Blarcamesine skulle begrunde det lavere antal pts i forsøgene.
Hope so
- 80% of dosed patients had diarrhea
-
Anavex ACAD stiger ca. 1 milliard $ i MC på nyheden.
Godt for RETT patienterne - men også for Anavex!
Er også overbevist om, at 2-73 vil overgå ACAD og vil følge op på de gode resultater fra det første RETT US og endda forbedre dem med den øget dosis i Avartar - uden bivirkninger.
Skulle ACAD få en markedsgodkendelse først, får vi dog en prissætning, som Anavex kan læne sig op af.
Så ACAD kan faktisk bane vejen for et bedre behandling med 2-73, både hos myndighederne og på markedet.
( 1 milliard $ i øget MC for Anavex svarer til ca. kurs 30 $ )
Anavex burde dog stige langt mere, da det som tidligere skrevet vil underbygge hele platformen og styrke casen, når Anavex starter f.eks. fase 3 forsøget op i Fragile X, som har en ca. 8 gange større patientgruppe.Anavex
s og Nells ALS præsentation.
Hun kommer også rundt om andre resultater.
Understreger at Anavex har en hel platform til en potentiel bred CNS behandling. -
Anavex Bedre ALS præsentation link.
-
Mens vi venter på nyheder som forhåbentlig kommer snart, måske næste uge før RETT konferencen (jeg har i øvrigt læst at det koster 2000$ for at se med?) kan man lige tygge lidt på nedenstående indlæg:
Den super dygtige Sokol på Ihub er kommet med en meget grundig analyse af Anavex og 2-73 & 3-71, ja måske ikke an analyse men hvad Sigma-1R agonists kan gøre.
Anavex Life Sciences Corp (AVXL): Two Potentially Significant YE2021 Catal...
sokol: Two Potentially Significant YE2021 Catalysts. One is obviously the Avatar data. The other is phase 1 AVXL 3-71 data. Why is the latter potentially...
InvestorsHub (investorshub.advfn.com)
-
sokol Member Level Saturday, 12/11/21 12:40:15 PM
Re: None 0
Post # of 339577Two Potentially Significant YE2021 Catalysts. One is obviously the Avatar data. The other is phase 1 AVXL 3-71 data. Why is the latter potentially significant? 3-71 is considered to be "good at, focusing more on Frontotemporal dementia(FTD)'' according to Missling, and FTD overlaps and is related to Amyotrophic lateral sclerosis (ALS). Many of damaged functions in these two diseases, as in some other neurodegenerative diseases, are regulated by signalling between the endoplasmic reticulum and mitochondria, and this has stimulated investigations into the role of endoplasmic reticulum-mitochondria signalling in FTD/ALS disease processes. Recently, Anavex made an ALS presentation as posted by TTTav66: "Exploring SIGMAR1 Modulators for the Treatment of ALS", presented by Nell Rebowe of Anavex Life Sciences at the 4th Annual ALS ONE Research Symposium: https://www.youtube.com/watch?v=J5jj_Pmc9q0by.
It has been postulated for sometime that Sigma-1R agonists may improve the functions damaged in FTD and ALS.
ALS is a rare disorder that develops in 1.5 to 3 per 100,000 people every year in North American and European populations. Approximately 30,000 people are affected in the United States, with an estimated 5,000 new cases diagnosed each year. Is ALS the other rare disease indication that Anavex may announce? See slide 14 December 2021 presentation: "Initiation of potentially pivotal Phase 2/3 clinical trial for the treatment of a new, rare disease indication -expected 1H 2022". However, why would it be a Phase 2/3 clinical trial?
Once the 3-71 data is available Missling indicates that Anavex may move forward with FTD and any other related dementia indication. "So, we have mentioned that we will move ahead with frontotemporal dementia, but we'd like to have really the solid phase 1 data in hand before we say we commit to this. And -- but we'll definitely move forward with FTD or any other related dementia indication." When the phase 1 3-71 data is presented, maybe we will learn more about what other FTD related indications Anavex may explore. However, from the recent Nell Rebowe presentation, we may surmise that positive 3-71 data for FTD will indicate promise for a future Anavex clinical trial for ALS. We may also learn whether any prospective Anavex ALS trial will involve either 2-73 or 3-71 or both.
See supporting research 1-13 below.
- Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice
Abstract
Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive weakness, muscle atrophy, and paralysis due to the loss of upper and lower motoneurons (MNs). Sigma-1 receptor (sigma-1R) activation promotes neuroprotection after ischemic and traumatic injuries to the central nervous system. We recently reported that sigma-1R agonist (PRE-084) improves the survival of MNs after root avulsion injury in rats. Moreover, a mutation of the sigma-1R leading to frontotemporal lobar degeneration/amyotrophic lateral sclerosis (ALS) was recently described in human patients. In the present study, we analyzed the potential therapeutic effect of the sigma-1R agonist (PRE-084) in the SOD1G93A mouse model of ALS. Mice were daily administered with PRE-084 (0.25 mg/kg) from 8 to 16 weeks of age. Functional outcome was assessed by electrophysiological tests and computerized analysis of locomotion. Histological, immunohistochemical analyses and Western blot of the spinal cord were performed. PRE-084 administration from 8 weeks of age improved the function of MNs, which was manifested by maintenance of the amplitude of muscle action potentials and locomotor behavior, and preserved neuromuscular connections and MNs in the spinal cord. Moreover, it extended survival in both female and male mice by more than 15 %. Delayed administration of PRE-084 from 12 weeks of age also significantly improved functional outcome and preservation of the MNs. There was an induction of protein kinase C-specific phosphorylation of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor in SOD1G93A animals, and a reduction of the microglial reactivity compared with untreated mice. PRE-084 exerts a dual therapeutic contribution, modulating NMDA Ca2+ influx to protect MNs, and the microglial reactivity to ameliorate the MN environment. In conclusion, sigma-1R agonists, such as PRE-084, may be promising candidates for a therapeutical strategy of ALS.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480575/
- There's Something Wrong with my MAM; the ER-Mitochondria Axis and Neurodegenerative Diseases
Sebastien Paillusson 1 , Radu Stoica 1 , Patricia Gomez-Suaga 1 , Dawn H W Lau 1 , Sarah Mueller 1 , Tanya Miller 2 , Christopher C J Miller 3
Affiliations expand
PMID: 26899735 PMCID: PMC4780428 DOI: 10.1016/j.tins.2016.01.008
Free PMC article
AbstractAlzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis with associated frontotemporal dementia (ALS/FTD) are major neurodegenerative diseases for which there are no cures. All are characterised by damage to several seemingly disparate cellular processes. The broad nature of this damage makes understanding pathogenic mechanisms and devising new treatments difficult. Can the different damaged functions be linked together in a common disease pathway and which damaged function should be targeted for therapy? Many functions damaged in neurodegenerative diseases are regulated by communications that mitochondria make with a specialised region of the endoplasmic reticulum (ER; mitochondria-associated ER membranes or 'MAM'). Moreover, several recent studies have shown that disturbances to ER-mitochondria contacts occur in neurodegenerative diseases. Here, we review these findings.
There's Something Wrong with my MAM; the ER-Mitochondria Axis and Neurodegenerative Diseases - PubMed
Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis with associated frontotemporal dementia (ALS/FTD) are major neurodegenerative diseases for which there are no cures. All are characterised by damage to several seemingly disparate cellular processes. The broad natu …
PubMed (pubmed.ncbi.nlm.nih.gov)
- The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins
Alice Dreser 1 , Jan Tilmann Vollrath 1 , Antonio Sechi 2 , Sonja Johann 3 , Andreas Roos 1 4 5 , Alfred Yamoah 1 , Istvan Katona 1 , Saeed Bohlega 6 , Dominik Wiemuth 7 , Yuemin Tian 7 , Axel Schmidt 7 , Jörg Vervoorts 8 , Marc Dohmen 8 , Cordian Beyer 3 , Jasper Anink 9 , Eleonora Aronica 9 , Dirk Troost 9 , Joachim Weis 1 , Anand Goswami 1
Affiliations expand
PMID: 28622300 PMCID: PMC5596426 DOI: 10.1038/cdd.2017.88
Free PMC article
AbstractAmyotrophic lateral sclerosis (ALS) is characterized by the selective degeneration of motor neurons (MNs) and their target muscles. Misfolded proteins which often form intracellular aggregates are a pathological hallmark of ALS. Disruption of the functional interplay between protein degradation (ubiquitin proteasome system and autophagy) and RNA-binding protein homeostasis has recently been suggested as an integrated model that merges several ALS-associated proteins into a common pathophysiological pathway. The E102Q mutation in one such candidate gene, the endoplasmic reticulum (ER) chaperone Sigma receptor-1 (SigR1), has been reported to cause juvenile ALS. Although loss of SigR1 protein contributes to neurodegeneration in several ways, the molecular mechanisms underlying E102Q-SigR1-mediated neurodegeneration are still unclear. In the present study, we showed that the E102Q-SigR1 protein rapidly aggregates and accumulates in the ER and associated compartments in transfected cells, leading to structural alterations of the ER, nuclear envelope and mitochondria and to subsequent defects in proteasomal degradation and calcium homeostasis. ER defects and proteotoxic stress generated by E102Q-SigR1 aggregates further induce autophagy impairment, accumulation of stress granules and cytoplasmic aggregation of the ALS-linked RNA-binding proteins (RBPs) matrin-3, FUS, and TDP-43. Similar ultrastructural abnormalities as well as altered protein degradation and misregulated RBP homeostasis were observed in primary lymphoblastoid cells (PLCs) derived from E102Q-SigR1 fALS patients. Consistent with these findings, lumbar a-MNs of both sALS as well as fALS patients showed cytoplasmic matrin-3 aggregates which were not co-localized with pTDP-43 aggregates. Taken together, our results support the notion that E102Q-SigR1-mediated ALS pathogenesis comprises a synergistic mechanism of both toxic gain and loss of function involving a vicious circle of altered ER function, impaired protein homeostasis and defective RBPs.
The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins - PubMed
Amyotrophic lateral sclerosis (ALS) is characterized by the selective degeneration of motor neurons (MNs) and their target muscles. Misfolded proteins which often form intracellular aggregates are a pathological hallmark of ALS. Disruption of the functional interplay between protein degradation (ubi …
PubMed (pubmed.ncbi.nlm.nih.gov)
- Disruption of ER-mitochondria signalling in fronto-temporal dementia and related amyotrophic lateral sclerosis
Abstract
Fronto-temporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two related and incurable neurodegenerative diseases. Features of these diseases include pathological protein inclusions in affected neurons with TAR DNA-binding protein 43 (TDP-43), dipeptide repeat proteins derived from the C9ORF72 gene, and fused in sarcoma (FUS) representing major constituent proteins in these inclusions. Mutations in C9ORF72 and the genes encoding TDP-43 and FUS cause familial forms of FTD/ALS which provides evidence to link the pathology and genetics of these diseases. A large number of seemingly disparate physiological functions are damaged in FTD/ALS. However, many of these damaged functions are regulated by signalling between the endoplasmic reticulum and mitochondria, and this has stimulated investigations into the role of endoplasmic reticulum-mitochondria signalling in FTD/ALS disease processes. Here, we review progress on this topic.Facts
ER-mitochondria signalling is disrupted by a number of FTD/ALS-linked insults. These include TDP-43, FUS, mutant SOD1, and loss of the Sigma-1 receptor.For TDP-43 and FUS this disruption involves breaking of the VAPB-PTPIP51 ER-mitochondria tethering proteins via activation of GSK3ß.
https://www.nature.com/articles/s41419-017-0022-7
- Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis
Abstract
Sigma-1 receptor (S1R) is an endoplasmic reticulum (ER) chaperone that not only regulates mitochondrial respiration but also controls cellular defense against ER and oxidative stress. This makes S1R a potential therapeutic target in amyotrophic lateral sclerosis (ALS). Especially, as a missense mutation E102Q in S1R has been reported in few familial ALS cases. However, the pathogenicity of S1RE102Q and the beneficial impact of S1R in the ALS context remain to be demonstrated in vivo. To address this, we generated transgenic Drosophila that expresses human wild-type S1R or S1RE102Q. Expression of mutant S1R in fly neurons induces abnormal eye morphology and locomotor defects in a dose-dependent manner. This was accompanied by abnormal mitochondrial fragmentation, reduced adenosine triphosphate (ATP) levels and a higher fatigability at the neuromuscular junction during high energy demand. Overexpressing IP3 receptor or glucose transporter mitigates the S1RE102Q-induced eye phenotype, further highlighting the role of calcium and energy metabolism in its toxicity. More importantly, we showed that wild-type S1R rescues locomotor activity and ATP levels of flies expressing the key ALS protein, TDP43. Moreover, overexpressing wild-type S1R enhances resistance of flies to oxidative stress. Therefore, our data provide the first genetic evidence that mutant S1R recapitulates ALS pathology in vivo while increasing S1R confers neuroprotection against TDP43 toxicity.- FTD and ALS: a tale of two diseases
Abstract
The first reports of disorders that in terms of cognitive and behavioral symptoms resemble frontotemporal dementia (FTD) and in terms of motor symptoms resemble amyotrophic lateral sclerosis (ALS) bring us back to the second half of the 1800s. Over the last 150 years, and especially in the last two decades, there has been growing evidence that FTD signs can be seen in patients primarily diagnosed with ALS, implying clinical overlap among these two disorders. In the last decade pathological investigations and genetic screening have contributed tremendously in elucidating the pathology and genetic variability associated with FTD and ALS. To the most important recentdiscoveries belong TAR DNA binding protein [TARDBP or TDP-43] and the fused in sarcoma gene [FUS] and their implication in these disorders. FTD and ALS are the focus of this review which aims to 1. summarize clinical features by describing the diagnostic criteria and specific symptomatology, 2. describe the morphological aspects and related pathology, 3. describe the genetic factors associated with the diseases and 4. summarize the current status of clinical trials and treatment options.A better understanding of the clinical, pathological and genetic features characterizing FTD and ALS will shed light into overlaps among these two disorders and the underpinning mechanisms that contribute to the onset and development. Nevertheless, advancements in the knowledge of the biology of these two disorders will help developing novel and, hopefully, more effective diagnostic and treatment options.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801195/
- The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two diseases that form a broad neurodegenerative continuum. Considerable effort has been made to unravel the genetics of these disorders, and, based on this work, it is now clear that ALS and FTD have a significant genetic overlap. TARDBP, SQSTM1, VCP, FUS, TBK1, CHCHD10, and most importantly C9orf72, are the critical genetic players in these neurological disorders. Discoveries of these genes have implicated autophagy, RNA regulation, and vesicle and inclusion formation as the central pathways involved in neurodegeneration. Here we provide a summary of the significant genes identified in these two intrinsically linked neurodegenerative diseases and highlight the genetic and pathological overlaps.
Frontiers | The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two diseases that form a broad neurodegenerative continuum. Considerable effort has...
Frontiers (www.frontiersin.org)
- FRONTOTEMPORAL DEMENTIA VS. ALS
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, are two deeply related diseases - in many cases they are even found to be co-occurring.
Frontotemporal Dementia vs. ALS
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, are two deeply related diseases – in many cases they are even found to be co-occurring.
ALS Therapy Development Institute (www.als.net)
- U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
...Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal demen
- Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX3-71 (AF710B)
...Anavex is developing ANAVEX
3-71 initially for the treatment of Frontotemporal Dementia (FTD), for which ANAVEX3-71 was previously granted orphan drug designation by the FDA. ANAVEX3-71 demonstrated disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.....Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)
NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical...
GlobeNewswire News Room (www.globenewswire.com)
- https://www.fool.com > call-transcripts > 2021/12/02
Dec 2, 2021 - AVXL earnings call for the period ending September 30, 2021 ...
Yun Zhong -- BTIG -- Analyst
OK. Then I think I didn't see an update on the 3-71 program in 2020 -- sorry, 2022 in terms of upcoming milestones, so I just wanted to check if frontotemporal dementia is still going to be the first indication for that program, and when do you expect a study potentially to start?
Christopher Missling -- President and Chief Executive Officer
Right. **So, we have mentioned that we will move ahead with frontotemporal dementia, but we'd like to have really the solid phase 1 data in hand before we say we commit to this. And -- but we'll definitely move forward with FTD or any other related dementia indication. **
......
Christopher Missling
So the two compounds (2-72 and 3-71) came from different angles and different labs but they are now moving more into what we call, we try to learn as we go. But so far we could not find parable assay other than a very early preclinical assay of target engagement. And there are differences in the affinities of the Sigma 1 receptor and also difference to the muscarinic receptor, which we believe is also important.And ultimately we will be only able to see really the difference of the two if we run really both indication world drug and the same indication in the same trial. So, we think that each drug has its own merits and it could very well be that 3-71 is really good at, focusing more on Frontotemporal dementia, which we had offered as ignition for and could also be very good at Alzheimer but right now we have 273 more advance, so we will eventually find out......
-
Top-line data Phase 1 ANAVEX
3-71 clinical trial -expected YE2021 (slide 14 Dec. 2021 presentation) -
ALS, Cognitive Impairment & Dementia - ALS Association
Is ALS related to dementia?
In ALS, some individuals develop dementia that most commonly presents as FTD, others develop cognitive and/or behavioral impairment without dementia, and some patients never develop any cognitive or behavioral impairment. -
Anavex Ja- der er et meget højt niveau på IHUB.
Der er flere der arbejder indenfor området og kan sætte sig helt ind i videnskaben - og samtidig er gode til at formidle det videre.
Ja - der en RETT konference den 14. - 15. december 2021.
Missling er på dag 2 den 15. dec.9:40 am Utilizing Precision Genetic Medicine to Treat Rare Neurodevelopmental Diseases: Focusing on Rett Syndrome
Chrisopher U Missling
President & CEO, Anavex Life Sciences
Synopsis
Requirement of clear understanding of target engagement
Importance of predictive biomarker of response correlating with efficacy
Relevance of appropriate efficacy endpointshttps://neurodevelopmental-drug-development.com/program/day-two/
Lidt spekulation:
Tror ikke Anavex har resultaterne klar fra Avatar til på onsdag den 15., men hvis de har, så bliver de vel offentliggjort og evt. gennemgået på et ekstraordinært PR/event.
Dvs. nu på mandag eller tirsdag.
Deltagelsen på RETT konferencen må have været planlagt nogle uger, så Misslings fremlægning kan evt. kun være basseret på RETT US.Omvendt må Missling på dette tidspunkt have et vist kendskab til patienterne fra de forskellige åbne RETT forsøg - RETT US, Avatar og Excellence.
På den baggrund ville det være lidt forkert/misvisende, hvis Missling skulle gennemgå ovennævnte punkter på konferencen, hvis han evt. lå inde med en viden om, at man ikke så nogen effekt hos disse OLE patienter?Så i min optik, må deltagelsen af Missling på denne konference på nuværende tidspunkt, være et udtryk for, at man har set positive ting fra OLE forsøgene ( og måske Avatar ) - ellers ville Anavex nok have undgået fokus på RETT lige nu og holdt en lav profil?
-
Anavex optages i Nasdaq Biotechnology Index
https://www.bloomberg.com/press-releases/2021-12-11/annual-changes-to-the-nasdaq-biotechnology-index per 20/12
Så må der vel være nogle index-trackere og ETF'er der skal købe ind? -
Anavex. JP Morgan konference den 13. januar 2022.
Live webcast kl. 17.15 - DK tid.
https://jpmorgan.metameetings.net/events/healthcare22/sessions/40488-anavex-life-sciences-corp/webcast?gpu_only=true&kiosk=trueJP Morgan Healthcare Conference, er en af de større konferencer - mon ikke Anavex nu er sikker på, at de har resultater klar fra Avatar og nok også fra 3-71 i FTD.
Anavex ville vel heller ikke udstille sig selv på en sådan vigtig konference, hvis man troede eller måske allerede nu vidste, at resultaterne var dårlige?
Ville man så ikke holde en lav profil? -
Anavex JP Morgan er en af de største iflg. IHUB.
JP Morgan is the biggest and most prestigious healthcare conference of the year. Being invited to present is a big deal. Invitations are typically reserved for JPM banking clients (or wannabe banking clients), or companies that are in a therapeutic space of particular interest.
Every biotech company dreams of being invited to present. Few are. I'm not saying the presentation will or won't be a market-moving event from a content perspective but nevertheless it is not insignificant that Missling will be presenting because the cream of the crop of biotech investors as well as healthcare journalists attend. There are also all kinds of social networking events.
Så et perfekt sted og tidspunkt for Anavex, at komme i rampelyset - hvis de da har noget at skyde med!
- Igen tror simpelthen ikke Missling ville stille sig op på den scene, hvis ikke han havde noget ekstraordinært at komme med!!
Ville dog også passe mig fint aht. til beskatning på mine aktiesparekontoer, hvis Anavex trak spændingen ud til efter 31. december 2021 - så håber lidt Missling heller ikke overholder annoncerede deadline denne gang - bare skidtet virker!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind